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Optimizing medication appropriateness in
older adults: a randomized clinical
interventional trial to decrease
anticholinergic burden
Daniela C. Moga1,2,3*, Erin L. Abner2,3, Dorinda N. Rigsby1, Lynne Eckmann4, Mark Huffmyer4, Richard R. Murphy3,5,
Beth B. Coy3 and Gregory A. Jicha3,5
Abstract
Background: The complexity of medication therapy in older adults with multiple comorbidities often leads to
inappropriate prescribing. Drugs with anticholinergic properties are of particular interest because many are not
recognized for this property; their use may lead to increased anticholinergic burden resulting in significant health
risks, as well as negatively impacting cognition. Medication therapy management (MTM) interventions showed
promise in addressing inappropriate medication use, but the effectiveness of targeted multidisciplinary team
interventions addressing anticholinergic medications in older populations is yet to be determined.
Methods: We conducted an 8-week, parallel-arm, randomized trial to evaluate whether a targeted patient-centered
pharmacist–physician team MTM intervention (“targeted MTM intervention”) reduced the use of inappropriate
anticholinergic medications in older patients enrolled in a longitudinal cohort at University of Kentucky’s Alzheimer’s
Disease Center. Study outcomes included changes in the medication appropriateness index (MAI) targeting
anticholinergic medications and in the anticholinergic drug scale (ADS) score from baseline to the end of study.
Results: Between October 1, 2014 and September 30, 2015 we enrolled and randomized 50 participants taking at least
one medication with anticholinergic properties. Of these, 35 (70%) were women, 45 (90%) were white, and 33 (66%) were
cognitively intact (clinical dementia rating [CDR] = 0); mean age was 77.7 ± 6.6 years. At baseline, the mean
MAI was 12.6 ± 6.3; 25 (50%) of the participants used two or more anticholinergics, and the mean ADS score
was 2.8 ± 1.6. After randomization, although no statistically significant difference was noted between groups, we identified
a potentially meaningful imbalance as the intervention group had more participants with intact cognition, and thus
included CDR in all of the analyses. The targeted MTM intervention resulted in statistically significant CDR adjusted
differences between groups with regard to improved MAI (change score of 3.6 (1.1) for the MTM group as compared
with 1.0 (0.9) for the control group, p = 0.04) and ADS (change score of 1.0 (0.3) for the MTM group as compared with
0.2 (0.3) for the control group, p = 0.03).
(Continued on next page)
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Conclusions: Our targeted MTM intervention resulted in improvement in anticholinergic medication appropriateness and
reduced the use of inappropriate anticholinergic medications in older patients. Our results show promise in an area of
great importance to ensure optimum outcomes for medications used in older adults.
Trial registration: ClinicalTrials.gov NCT02172612. Registered 20 June 2014.
Keywords: Anticholinergic medication, Medication therapy management intervention, Older adults, Alzheimer’s
Disease Center
Background
Medication therapy is a fundamental component of the
care of older patients, but evidence suggests that
pharmacotherapy in this population is often inappropri-
ate. Lau et al. [1] evaluated the magnitude of this
problem in older patients followed in the National
Alzheimer’s Coordinating Center cohort between 2005
and 2007. Using the Beers 2003 criteria for potentially
inappropriate prescribing [2], they estimated that 20% of
the older subjects without dementia and 15% of those
with dementia had at least one potentially inappropriate
prescription; a strong association was seen between the
number of medications used and the odds of having at
least one inappropriate prescription [1]. Centers for
Disease Control and Prevention estimated that about
36% of adults over 60 years old in the United States used
five or more drugs in the past month during 2007–2008
[3]. A recent Canadian study in frail older people found
that the patients took an average of 15 medications
(range 6–28), with 8.9 drug-related problems per patient
(range 3–19) [4].
Different medications and medication classes are
known to cause cognitive impairment that can range
from acute confusion to chronic impairment. Relevant
to the current study, drugs with anticholinergic proper-
ties can play an important role in causing cognitive
impairment. Cholinergic antagonists deserve this special
attention given the significant role played by the cholin-
ergic system in the brain in activities such as attention,
awareness, and selection of relevant stimuli in the
environment [5, 6]. Anticholinergic medications have
been identified as a group of drugs contraindicated in
patients with dementia, largely due to their potentially
severe adverse effects on cognition and psychiatric
symptoms, including increasing psychotic symptoms and
agitation [7, 8]. Challenge studies have shown that
people with different levels of cognitive impairment are
highly sensitive to anticholinergics and can experience
severe central nervous system adverse effects like
memory disturbances, delirium, agitation, and psychotic
symptoms, including hallucinations [7]. A placebo-
controlled crossover study demonstrated the significant
effect of cholinergic antagonists in patients with demen-
tia; patients enrolled in this trial experienced memory
impairment, restlessness, disjointed speech, drowsiness,
agitation, and hallucinations after scopolamine adminis-
tration [9].
The role of medication management was formally
recognized by the Medicare Prescription Drug, Improve-
ment, and Modernization Act of 2003 that describes the
role of medication therapy management (MTM)
programs in reducing the risk of adverse drug events
[10]. Pharmacists have been involved in different
approaches for the optimization of prescribing and ra-
tional medication use in older people, and play a key
role in the effective implementation of MTM programs.
Previous studies brought evidence on the efficacy of col-
laborative, multidisciplinary (i.e., pharmacist–primary
care provider) interventions to improve medication use
in older patients at risk [11], and also on the importance
of adopting a patient-centered approach as a fundamen-
tal philosophy of pharmaceutical care [12]. However, the
literature on the impact of such interventions on redu-
cing inappropriate anticholinergic medications and
whether such interventions improve clinical outcomes
(including improvement in cognitive function) is rather
limited [11, 13]. Specifically, previous studies addressing
MTM interventions focused primarily on polypharmacy,
without specification of medication type or class, rather
than the specific use of anticholinergic medication, to
evaluate appropriate use [11], or have focused on pa-
tients in long-term care rather than a more generalizable
population of community-dwelling older adults [13]. Ef-
fective patient-centered interventions in which a clinical
pharmacist collaborates with the patient’s physician to
reduce anticholinergic burden might improve cognitive
performance and functionality in the older population.
Prescribing for older patients can be more challenging
due to factors such as age-related changes and multiple
comorbidities. The right balance between concomitantly
treating several chronic conditions and avoiding
medication-related negative effects is an important ob-
jective for healthcare providers, yet one that might be
hard to achieve [14]. The ultimate goal of improving
health outcomes in general, and brain health in particu-
lar, by optimizing medication use in older patients might
be a complex process. Identifying the best approach to
make this change is an essential first step en route to
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improving health. Therefore, we sought to investigate
whether a targeted multidisciplinary team intervention
would be successful at reducing inappropriate anti-
cholinergic medication use in older patients enrolled in
a cohort at the Alzheimer’s Disease Center (ADC) at
University of Kentucky (UK).
Methods
Study design
We conducted an 8-week, parallel-arm, randomized trial to
evaluate a targeted patient-centered pharmacist–physician
team MTM intervention (“targeted MTM intervention”) to
improve anticholinergic medication appropriateness and re-
duce the use of inappropriate anticholinergic medications
in older patients enrolled in the ADC cohort. We defined
inappropriate anticholinergic medication use in a two-
step approach. All anticholinergic medications taken
by each participant were labeled “potentially inappro-
priate” and were subject to review by the study team.
The second step was conducted during the targeted
MTM intervention when each of the previously
flagged medications was evaluated using a risk–benefit
approach with final recommendations based on the
participant’s input and preference. The study was
approved by the Institutional Review Board at UK.
All participants provided written informed consent.
Inclusion and exclusion
Patients were considered for inclusion in our study if they
met the following eligibility criteria: actively enrolled in
the ADC cohort; 65 years of age and older; reporting at
least one drug with anticholinergic properties [15–17] at
their annual ADC visit; and willing to participate in our
intervention study. Patients were excluded if they had
moderate or severe dementia as measured by a Clinical
Dementia Rating (CDR) [18] global score ≥ 2, or lived in a
long-term care facility at the time of enrollment.
Participant recruitment
In short, between October 1, 2014 and September 30,
2015 we screened the records for participants actively
enrolled in the ADC cohort within 1 week of their
scheduled annual visit. We identified study-eligible pa-
tients who reported at least one anticholinergic drug and
mailed them a letter briefly introducing our study. One
to two weeks after mailing the letter, the potential
participant received an enrollment call from the study
team; once verbal consent for participation was granted,
the medication list was finalized and additional details
about the medications taken were collected. Between the
enrollment call and the first study visit (2 weeks after
enrollment), the pharmacist evaluated the appropriate-
ness of the anticholinergic medication(s) and outlined
points to address in case the participant was randomized
to intervention.
Randomization
After enrollment in the study, patients were randomized to
either the intervention or the control group using a simple
block randomization scheme (50 subjects randomized into
five blocks), which was generated using the web site Rando-
mization.com (http://www.randomization.com). The study
statistician prepared 50 sealed opaque envelopes containing
the sequential randomization assignments, and these were
provided to the study principal investigator, who had no
knowledge of the randomization assignments contained
within. Each envelope was opened only after the study
pharmacist completed the baseline medication review. Be-
cause the intervention was educational in nature, complete
blinding of the intervention was not possible. However, we
attempted to minimize potential bias and achieve the max-
imum level of blinding possible by this design. Specifically,
when reviewing the medication list prior to the interven-
tion, both the study pharmacist and the licensed prescriber
at the ADC were unaware of the group allocation. In
addition, data analysis was blinded to the intervention.
Study procedures
There were two total study visits for both the interven-
tion and control groups (Fig. 1). At the first study visit,
all participants were provided with generic information
available from the US Food and Drug Administration,
Fig. 1 Study procedures. ADC Alzheimer’s Disease Center
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encouraging patients to be proactive in talking to their
health care providers about their medications (http://
www.fda.gov/drugs/resourcesforyou/ucm079453.htm). In
addition, those participants randomized to the interven-
tion group met with the pharmacist–clinician team that
conducted the targeted MTM intervention. The end-of-
study visit was scheduled 8 weeks after enrollment. At
this visit, all participants provided updated information
on their medication use to allow us to determine any
changes from baseline, and completed the Short Form
Health Survey (SF-36) and the end-of-study question-
naire. Those in the control group were given the oppor-
tunity to discuss any questions or concerns about their
medications with the study pharmacist.
Intervention
The targeted MTM intervention was based on the
pharmacist–clinician team drug review between enroll-
ment and visit 1. Typical MTM interventions evaluate
all medications used by a patient and determine treat-
ment necessity and potential changes; our intervention
only targeted medications known to have anticholinergic
properties. For patients randomized to the intervention
group, the study pharmacist provided a revised medica-
tion plan based on the drug review, which was discussed
with the participant and/or their Legally Authorized
Representative. Specifically, the proposed plan attempted
to recommend discontinuation or replacement of any
potentially inappropriate drug with anticholinergic prop-
erties, with safer drug alternatives (i.e., with less or no
anticholinergic activity). When drug alternatives were
unavailable, reduction in dosage was recommended
whenever possible to reduce the anticholinergic burden
[19]. Similar to routine clinical practice, the study
clinician ultimately made the recommendations about
prescription changes to the participant, while the study
pharmacist was responsible for recommendations and
provision of information to educate the participant
about medication safety and the importance of patient
involvement in medication awareness and oversight.
Appropriate changes were determined by the licensed
prescriber, but the participant had the freedom to accept
or reject the recommendations.
Study endpoints
The coprimary endpoints measured the impact of the
targeted MTM intervention on potentially inappropri-
ate anticholinergic use by evaluating change from
baseline to end of study in: appropriateness of anti-
cholinergic medication prescribing, as measured by
the medication appropriateness index (MAI) [20]; and
anticholinergic burden as measured by the number of
anticholinergic drugs used and the anticholinergic
drug scale (ADS) [16].
The MAI rates each medication based on 10 different
criteria related to indication, effectiveness, dosing and
medication-taking behavior, potential for drug–drug or
drug–disease interactions, duplication of therapy, patient
acceptability of the medication, and whether the medica-
tion is the least expensive option for the specific indica-
tion. Each criterion has explicit instructions and
examples to guide evaluation, and the study pharmacist
rates whether the particular medication was “appropri-
ate”, “marginally appropriate”, or “inappropriate”; the
final MAI score can range from 0 (totally appropriate) to
18 (completely inappropriate) [20]. MAI assessments
made by a clinical pharmacist and a physician (i.e.,
internist and geriatrician) demonstrate high inter-rater
(κ = 0.83) and intra-rater (κ = 0.92) reliability [20]. Our
focus was on drugs with anticholinergic properties, ei-
ther obtained by prescription or over the counter. Medi-
cation appropriateness at baseline was assessed in a
blinded manner, before randomization.
Anticholinergic burden (and change from baseline to
end of study) was measured using the updated version
of the ADS score. The updated version of the scale was
obtained from the lead author; changes from the original
scale include reassigned scores for some medications
(e.g., change from ADS = 0 to ADS = 1 for loratadine, or
from ADS = 1 to ADS = 0 for oxazepam), and new scores
for medications that were unavailable or unassessed at
the time the original scale was published. The ADS has
four levels for each included drug, ranging from 0 (no
known anticholinergic activity) to 3 (markedly
anticholinergic activity) by comparison with serum anti-
cholinergic activity [16]. Of the existing anticholinergic
scales, the ADS categorized the largest number of medi-
cations for anticholinergic activity [21]. The summation
of anticholinergic activity level for all of the drugs taken
by a patient reflected the total anticholinergic burden for
the participant, with higher scores indicating higher
burden [16].
In addition, we created a composite binary outcome
measure to incorporate a change in dose when treat-
ment discontinuation was not possible. Specifically, a
reduction in anticholinergic medications (yes/no) was
defined in the case of either discontinuation or dose
reduction.
The secondary endpoint included the change in per-
ceived health status from baseline to the end-of-study
visit as measured using the SF-36, a validated instrument
that evaluates eight health domains categorized into
three major health attributes: functional status (i.e.,
physical functioning, social functioning, role limitations
due to physical problems, role limitations due to emo-
tional problems); well-being (mental health, vitality, bod-
ily pain); and general health perception (an overall
evaluation of health) [22]. In addition, these eight health
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domains can be grouped into two component scores:
physical and mental health [23]. Previous research re-
ported that the SF-36 correlated well with the Sickness
Impact Profile scores, a more thorough health status
evaluation [24, 25]. SF-36 summary scores range from 0
to 100, with lower scores indicating poorer perceived
health. Thus, a positive change from baseline to end of
study indicates improvement in perceived health. All
participants completed the baseline SF-36 as part of
their annual ADC assessment within the 2 weeks prior
to enrollment and again at the end-of-study visit.
At the end-of-study visit, we also asked participants to
complete a questionnaire asking about their experience
as part of the study and how they perceived the inter-
vention. We also investigated reasons for participation,
and whether our study impacted the pattern of commu-
nication between study participants and their health care
providers (i.e., physician and or pharmacist). The
additional file includes the end-of-study questionnaire as
used by our participants (see Additional file 1).
Statistical analysis
We used Student’s t tests (or Wilcoxon rank-sum tests for
nonnormally distributed variables) and chi-square or
Fisher’s exact tests to assess the comparability of study
groups after randomization. To examine the effect of the
intervention on prescribing appropriateness measured
using the MAI and ADS, we performed analysis of covari-
ance (ANCOVA), with the dependent variables being the
difference in scores between baseline and the end-of-study
measure. The impact of the intervention on reducing the
number of anticholinergic medications from baseline to
the end of study was assessed using Poisson regression
that also accounted for the number of medications the
participant was taking at baseline. For our composite
binary measure of reducing anticholinergic load, we con-
ducted logistic regression; to evaluate the robustness of
this measure of change, we also conducted a sensitivity
analysis using logistic regression restricted to participants
using moderate or strong anticholinergic medications. For
the perceived health status measure, because the SF-36
does not produce a single overall measure, analysis of
covariance was used to estimate the effect of the interven-
tion on the eight SF-36 health concepts and the two com-
ponent scores. For all of the analyses, our a-priori
statistical analysis plan considered controlling for any
variable that might have been significantly different be-
tween the two groups after randomization.
Power calculation
Based on previous studies using the MAI as the out-
come of interest, we calculated the sample size to detect
a clinically relevant mean difference of 1.0 between base-
line and the end-of-study assessment for the
intervention group. We estimated that 34 subjects in
total (17 per group) would be sufficient to detect this
difference with 80% power at a significance level of 0.05.
This was a rather conservative approach because previ-
ous studies showed that medication reconciliation inter-
ventions can determine a mean MAI change ranging
between 1.9 and 17 [26]. In order to account for the po-
tential loss to follow-up, we planned to enroll 25 partici-
pants for each group, for a total of 50 participants.
Results
Of the 266 records that were screened after a completed
visit to the ADC, 50 participants were enrolled and ran-
domized to either the control group or the intervention
group (Fig. 2). One participant was lost to follow-up and
was excluded from the analyses because no outcome
measures were available. Of the 27 different anticholinergic
medications reported at baseline and targeted for evalu-
ation, the most frequently used by our participants were
triamterene (ADS = 1, N = 7 (8.8%)), tolterodine (ADS = 3,
N = 6 (7.5%)), ranitidine (ADS = 2, N = 6 (7.5%), and fluox-
etine (ADS = 1, N = 6 (7.5%). Of the medications that were
discontinued, eight medications were classified as ADS = 3,
three were classified as ADS = 2, and six medications were
classified as ADS = 1. Specific medications that were
discontinued included tolterodine (N = 2, ADS = 3), diphen-
hydramine (N = 2, ADS = 3), fluoxetine (N = 2, ADS = 1),
and loratadine (N = 2, ADS = 1).
When assessing balance between group characteristics
at baseline, there were no statistically significant differ-
ences between those participants randomized to
intervention and the control group (Table 1).
Although CDR was not statistically significant when
assessed as a three-level variable, there was a potentially
meaningful imbalance such that the intervention group
had more participants with intact cognition. Thus, we
also assessed CDR as a dichotomous variable (CDR = 0
vs CDR > 0), and found a significant difference (p = 0.04).
Therefore, we decided to control for CDR in all of the
analyses. When evaluating the impact of the intervention
on the MAI and ADS, both the unadjusted and the ad-
justed (controlling for baseline CDR) analyses indicated
that the intervention was effective in reducing
anticholinergic load (Table 2). The number of anti-
cholinergic drugs was reduced significantly in the inter-
vention group. The adjusted analysis controlling for
baseline CDR and accounting for number of medications
at baseline resulted in a rate ratio of 5.1 (95% confidence
interval (CI): 1.6, 16.6), meaning the intervention group
was over five times as likely as the control group to
discontinue an inappropriate anticholinergic medication.
Furthermore, the logistic regression model adjusted for
baseline CDR indicated that the intervention group had
higher odds of lowering anticholinergic load (i.e.,
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composite outcome for change) as compared with the
control group (odds ratio (OR) = 12.5; 95% CI: 2.3, 100).
Similarly, when restricting the analysis to those using
moderate or strong anticholinergic medications, the
CDR adjusted odds of lowering anticholinergic load were
higher for the intervention group (OR = 7.5, 95% CI: 1.3,
44.6).
When evaluating our secondary outcome of perceived
health status at baseline, no significant differences were
observed between the two study groups, with the excep-
tion of the mental health domain (Table 3). This
difference persisted in the adjusted analysis, where the
intervention group showed an adjusted mean positive
change of 1.1 (SEM = 3.3), which was not statistically
significant, compared with a negative change (worsen-
ing) in the control group where the mean change was –
7.9 (SEM = 2.8) (p = 0.02). We note that adjustment for
CDR changed the unadjusted point estimates for the
mental health domain, but the absolute difference was
similar (~11 vs ~9).
With regard to their reasons for participation and per-
ceptions of the study, the majority of the participants
stated either the desire to help themselves or others, or
curiosity, as the main reasons for participation. Before
participating in our study, 60% of the participants agreed
or strongly agreed about discussing the medications they
were taking with their doctor. Fewer participants agreed
or strongly agreed about discussing medication-related
issues with a pharmacist (32%), or with both their doctor
and pharmacist (28%). After participating in the study,
more participants agreed or strongly agreed that they
will discuss their medication with their doctor (74%) or
with their pharmacist (60%), and 52% agreed or strongly
agreed that they will discuss with both their doctor and
their pharmacist. Of the 50 participants enrolled in the
study, 86% agreed or strongly agreed with the statement
“After participating in this study I think it is important
for me to understand more about the medications I am
taking”, and the same proportion disagreed or strongly
disagreed with the statement “Participation in this study
added significant burden”.
Discussion
We conducted a randomized intervention to evaluate
the impact of a pharmacist–medical provider team
impact on lowering inappropriate anticholinergic medi-
cation use in older adults. Our study showed an im-
provement in medication appropriateness as measured
by the MAI and in anticholinergic load as measured by
the number of anticholinergic medications and by the
ADS. During the 8-week intervention, 44% (n = 11) of
the intervention group stopped taking at least one anti-
cholinergic medication, compared with just 8% (n = 2) of
the control group. With regard to measuring quality of
life, specifically the perceived health status, although
only the mental health domain of the SF-36 showed a
significant difference following our intervention (no
change for intervention, worsening for control), it is also
important to note that our targeted MTM intervention
did not negatively affect our study participants.
Fig. 2 Flow diagram: study participation and selection process
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Previous studies evaluated the impact of MTM inter-
ventions on optimizing pharmacologic therapies and re-
ducing inappropriate medication use. For instance,
Hanlon et al. [27] showed that the MAI was significantly
improved following a pharmacist-led MTM intervention
aimed at identifying any potential inappropriate medica-
tion used by veterans receiving care in one of the
Veterans Affairs Medical Centers. Similarly, studies
evaluating the effect of targeted MTM interventions on
specific medications also showed promising results with
significant improvement in medication appropriateness,
as measured by the MAI [28, 29]. However, the evidence
regarding the effect of targeted MTM interventions on
reducing inappropriate anticholinergic medication use in
older adults is very limited and has mainly targeted older
adults in nursing homes rather than those living in the
community. One study in Norway investigated whether
reducing the anticholinergic burden in long-term care
frail adults improves their cognitive function, and found
that the intervention was successful in reducing anti-
cholinergic load but did not show any statistically signifi-
cant improvement in cognition after the 8-week follow-
up [13]. A study in Finland recruited residents in
assisted living facilities in Helsinki to evaluate the impact
of a multidisciplinary team intervention to reduce
inappropriate medication use including anticholinergic
and psychotropic medications; the results published thus
far are promising in that the MTM intervention resulted
in a reduction of inappropriate medications [30]. Our
study results are in line with the existing evidence and
Table 1 Targeted MTM intervention: baseline participant characteristics
Demographics All subjects (N = 50) Control group (n = 25) MTM group (n = 25) p value
Age (years) 77.7 ± 6.6 79.1 ± 6.9 76.3 ± 6.2 0.13
Education (years) 16.1 ± 2.8 15.8 ± 3.0 16.5 ± 2.5 0.34
Female 35 (70.0) 17 (68.0) 18 (72.0) 0.76
Race 0.99
White 45 (90.0) 22 (88.0) 23 (92.0)
Black or African American 5 (10.0) 3 (12.0) 2 (8.0)
Clinical Dementia Rating 0.13
0 33 (66.0) 13 (52.0) 20 (80.0)
0.5 12 (24.0) 8 (32.0) 4 (16.0)
1.0 5 (10.0) 4 (16.0) 1 (4.0)
Anticholinergic medication use
Medication appropriateness index 12.6 ± 6.3 13.0 ± 4.4 12.2 ± 7.9 0.63
Anticholinergic drug scale 2.8 ± 1.6 2.9 ± 1.3 2.8 ± 1.9 0.73
Number of anticholinergic drugs
1 25 (50.0) 11 (44.0) 14 (56.0) 0.40
≥2 25 (50.0) 14 (56.0) 11 (44.0)
Used anticholinergic drugs with moderate/strong activity 31 (62) 18 (72) 13 (52) 0.14
RAND SF-36
Health domains
General health 67.7 ± 17.9 69.4 ± 14.8 66.0 ± 20.7 0.52
Physical functioning 67.4 ± 25.6 60.4 ± 25.9 74.2 ± 23.9 0.06
Bodily pain 66.6 ± 28.1 63.1 ± 25.8 70.0 ± 30.4 0.40
Role limitations, physical 53.1 ± 38.8 50.0 ± 33.8 56.3 ± 43.8 0.58
Mental health 82.6 ± 13.0 87.1 ± 9.4 78.2 ± 14.6 0.02
Vitality 56.1 ± 23.2 57.3 ± 23.2 55.0 ± 23.7 0.73
Social functioning 80.1 ± 22.7 80.7 ± 23.0 79.5 ± 22.8 0.85
Role limitation, emotional 81.3 ± 29.9 84.7 ± 21.9 77.8 ± 36.3 0.43
Component scores
Physical health 63.8 ± 22.5 60.7 ± 19.1 66.8 ± 25.3 0.35
Mental health 75.0 ± 17.8 77.5 ± 13.6 72.7 ± 21.0 0.35
Data presented as mean ± SD or N (%)
MTM medication therapy management, SF-36 Short Form Health Survey
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add important knowledge by showing that MTM inter-
ventions can be effective when targeting community-
dwelling older adults.
With regard to the impact of MTM interventions on
perceived health status measured using the SF-36, our re-
sults are similar to the findings from previous randomized
trials that reported no statistically significant or only min-
imal differences for the eight SF-36 domains [27, 31–33].
In addition, a recent Agency on Healthcare Research and
Quality review on MTM interventions in outpatient
settings included a meta-analysis of published studies to
evaluate the impact of MTM interventions on SF-36 do-
mains and showed no statistically significant differences in
all but one of the eight SF-36 domains, namely the ‘Vital-
ity’ domain [34]. In addition, having no negative impact
on any of the SF-36 domains due to the intervention is
also reassuring for the potential of an MTM intervention
to address inappropriate medication use.
Our study has several important strengths. The spe-
cialized care provided by clinicians at the UK ADC in
collaboration with pharmacists with extensive experience
in geriatric care allowed for complex medication
regimens to be evaluated and modified when deemed
necessary, without posing risks for participants. In
addition, we were able to recruit participants in a timely
fashion and had good response rates among those iden-
tified as eligible; our successful recruitment was facili-
tated by the collaboration with the UK ADC and the
positive reputation of the center in the local community.
Moreover, our loss to follow-up rate was low, with only
one participant who could not be tracked for the end-of-
study visit to determine outcomes. Thus, we are
confident in our interpretation of the results and the fact
that attrition bias was not influential.
Our study has some limitations. The 8-week follow-up
did not allow us to evaluate whether the intervention is
Table 3 Secondary outcomes: SF-36 change scores from baseline to end of studya
RAND SF-36 Control group (n = 24) MTM group (n = 25) p value
Health domains
General health –3.9 ± 14.9 4.3 ± 13.8 0.06
Physical functioning 3.6 ± 16.0 –5.2 ± 15.6 0.06
Bodily pain 1.8 ± 31.5 –6.8 ± 20.8 0.28
Role limitations, physical 4.6 ± 41.3 1.0 ± 32.5 0.75
Mental health –6.1 ± 12.7 4.8 ± 12.5 0.005
Vitality –4.9 ± 16.3 2.8 ± 12.9 0.08
Social functioning –1.7 ± 29.2 0.5 ± 20.6 0.76
Role limitation, emotional –6.1 ± 31.9 0.0 ± 32.6 0.53
Component scores
Physical health 1.5 ± 16.5 –1.2 ± 13.2 0.53
Mental health –4.7 ± 14.0 2.1 ± 12.9 0.09
Data presented as mean ± SD or N (%)
MTM medication therapy management, SF-36 Short Form Health Survey
aA negative result means a worsening on the measure between baseline and the end-of-study visit
Table 2 Primary outcomes: anticholinergic use change scores from baseline to end of studya
Control group (n = 24) MTM group (n = 25) p value
Unadjusted outcome (mean ± SD)
Medication appropriateness index –1.1 ± 3.1 –4.2 ± 5.1 0.02
Anticholinergic drug scale –0.2 ± 0.9 –1.2 ± 1.6 0.01
Number of anticholinergic drugs –0.1 ± 0.3 –0.6 ± 0.7 0.004
Adjusted outcomeb (mean ± SEM)
Medication appropriateness index –1.0 ± 0.9 –3.6 ± 1.1 0.04
Anticholinergic drug scale –0.2 ± 0.3 –1.0 ± 0.3 0.03
Number of anticholinergic drugs –0.04 ± 0.03 –0.2 ± 0.1 0.04
aA negative result means a lower measure at the end-of-study visit (improvement in medication appropriateness index, lower anticholinergic drug scale, and fewer
medications with anticholinergic properties)
bAdjusted for baseline Clinical Dementia Rating global score. Reduction in number of anticholinergic drugs is also adjusted for number of anticholinergic drugs
taken at baseline (as the offset in the Poisson model)
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sustainable following the end of study. Participants may
not be compliant with medication changes recom-
mended by the pharmacist–clinician team in the long
run, especially if primary care physicians are in disagree-
ment with medication changes recommended by the
pharmacist–clinician team. In addition, given the short
follow-up, we focused on measures including the impact
of the intervention on anticholinergic burden using the
ADS, medication appropriateness using the MAI, and
perception of health status using the SF-36. Measures of
longitudinal change in objective clinical status and cog-
nitive outcomes were not evaluated in the present study.
Further research should focus on measuring appropriate
objective clinical and cognitive outcomes that will neces-
sarily involve engaging subjects over more prolonged
periods of intervention in order to detect meaningful
change in these important outcome measures. From a
brain health perspective, our next steps would involve
an expansion of the intervention to assess its impact on
cognitive function. An important caveat in interpreting
the present findings lies in the lack of a universally
agreed-upon rating scale for anticholinergic burden.
Existing anticholinergic rating scales frequently differ in
the medications included and the severity of anticholin-
ergic activity attributed to specific medications and
classes of drugs. Despite this caveat, and the consider-
ation that the scale we selected to conduct our interven-
tion includes medications that might not be found on
other anticholinergic scales [35, 36], it is important to
note that the main objective of the study was to investi-
gate whether participants were open to change
medications deemed inappropriate. The fact that change
was embraced for medications with low and high anti-
cholinergic activity shows promise because it indicates
willingness on the patient’s side to collaborate with a
pharmacist–clinician team to maximize medication ap-
propriateness. Lastly, the fact that our intervention was
conducted by specialized providers and delivered to a
highly educated and highly motivated study population
may limit the generalizability of our results.
Conclusion
Physicians regularly monitor medical treatments for
their patients and change treatment plans when the
balance between risks and benefits is not appropriate.
However, sometimes the potential for a harmful effect is
not recognized; this is often the case for some drugs that
although having anticholinergic effects are not recog-
nized as such. The inclusion of a clinical pharmacist
with extensive experience in conducting medication
therapy management reviews added value for the brain
health care provided on a regular basis by clinicians at
the UK ADC clinic. Our results bring important evi-
dence on the feasibility of improving anticholinergic
medication use in older adults living in the community,
making this intervention a promising avenue for improving
brain health care.
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